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Paraneoplastic syndromes can precede the initial manifestation and diagnosis of cancer. Paraneoplastic syndromes
are a heterogeneous group of disorders caused by mechanisms other than the local presence of tumor cells. These
phenomena are mediated by humoral factors secreted by tumor cells or by tumor mediated immune responses.
Among paraneoplastic syndromes, chronic intestinal pseudo-obstruction (CIPO) is rare and represents a particularly
difficult clinical challenge. Paraneoplastic CIPO is a highly morbid syndrome characterized by impaired gastrointestinal
propulsion with symptoms and signs of mechanical bowel obstruction. Clinical outcomes of paraneoplastic CIPO
are often deleterious. The current standard of care for the management of CIPO includes supportive treatment
with promotility and anti-secretory agents. However, the majority of patients with CIPO eventually require the resection of
the non-functioning gut segment. Here, we present a 62-year-old patient with anti-Hu antibody associated paraneoplastic
CIPO and underlying small cell lung cancer who underwent treatment with cisplatin and etoposide. Herein, we
discuss diagnosis, prognosis, proposed mechanisms, treatment options, and future potential therapeutic strategies
of paraneoplastic CIPO.
Keywords: Paraneoplastic chronic intestinal pseudo-obstruction, Anti-Hu antibodies, Myenteric ganglioneuritis,
Small cell lung cancerBackground
Paraneoplastic syndromes are disorders associated with
cancer and reflect the interaction between tumor cells,
host cells, and cells of the immune system. They are not
a direct effect of the underlying malignancy and occur
at remote sites from the primary or metastatic lesions
[1,2]. Paraneoplastic neurologic syndromes (PNS) are rare
among the paraneoplastic syndromes, and less than 1% of
cancer patients are affected by PNS [1]. The pathogenesis
of PNS is incompletely understood, however it is thought
that immunologic factors such as auto-antibodies and
T-cell responses against the nervous system, as well as
a breakdown of immune tolerance, play an important
role [2-4]. Auto-antibody formation is thought to be trig-
gered by an aberrant expression of neuronal antigens
by tumor cells [1]. Examples of well-characterized auto-* Correspondence: tenzler@email.arizona.edu
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unless otherwise stated.antibodies in conjunction with PNS are type 1 anti-neuronal
nuclear (anti-Hu or ANNA1), anti-voltage gated calcium
channel, anti-Yo and anti-amphiphysin antibodies (Table 1)
[5]. Paraneoplastic CIPO is a rare PNS mainly associated
with small cell lung cancer and carcinoid tumor. Similar to
other PNS, the pathophysiologic mechanism hypothetically
involves auto-antibody mediated inflammation of the
nervous system.Case presentation
A 62-year-old gentleman with chronic obstructive pulmon-
ary disease (COPD) from chronic smoking presented with
worsening cough and constipation for three months.
Within the last year, the patient was recurrently treated
for COPD exacerbations without significant clinical im-
provement. The patient denied having had fever, pain, nau-
sea, vomiting, night sweats, or weight loss. Vital signs were
unremarkable and pertinent findings on physical exam in-
cluded mild wheezes on both lungs with decreased breath
sounds over the left upper lobe, enlarged left supraclavicu-
lar lymph nodes, and hypoactive bowel sounds. Laboratoryl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Antibodies in paraneoplastic neurologic syndromes
Antibody Paraneoplastic neurologic syndrome Associated malignancies
Anti-Hu (ANNA-1) Encephalomyelitis, cerebellar degeneration, sensory neuronopathy, autonomic dysfunction SCLC
Anti-Yo (PCA-1) Cerebellar degeneration Gynecological, breast
Anti-Ri (ANNA-2) Cerebellar degeneration, opsoclonus-myoclonus Gynecological, breast, SCLC
Anti-Tr (DNER) Cerebellar degeneration Hodgkin lymphoma
Anti-amphiphysin Stiff-person syndrome Breast, lung cancer
Anti-Ma2 (Ta) Limbic encephalitis Teratoma, lung cancer
Anti-CRMP5 (CV2) Encephalomyelitis, peripheral neuropathy SCLC, thymoma
Anti-recoverin Retinopathy SCLC




Anti-AChR Myasthenia gravis Thymoma
Anti-titin
Anti-ryanodine




Figure 1 CT scan of the chest. CT of the thorax (horizontal section)
showing a large mass measuring 4.6 × 12.0 × 8.1 cm, encasing the left
pulmonary artery and segmental branches (arrows).The mass also
abutts the left mainstem bronchus with partial encasement. Moderate-
sized left pleural effusion (arrow heads).
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(normal 136–145 mEq/L), however other results were all
within normal range. Computed tomography (CT) and
positron emission tomography (PET) scans showed a
large left upper lobe fludeoxyglucose (FDG)-avid mass
(standardized uptake value (SUV) 14.3) and enlarged
left supraclavicular lymph nodes with avid FDG uptake
(SUV 4.0) (Figures 1 and 2). Brain magnetic resonance
imaging (MRI) revealed no metastatic disease in the brain.
Subsequent fine-needle aspiration of the left supraclavicu-
lar mass and immunohistochemistry staining confirmed
small cell neuroendocrine cancer positive for thyroid tran-
scription factor (TTF-1) and synaptophysin confirming
the diagnosis of small cell lung cancer (SCLC). The disease
was determined as extensive disease due to the fact that
tumor/nodal volume was too large to be encompassed in
a tolerable radiation plan. During the hospital course, the
patient’s bowel movements further declined despite an ag-
gressive bowel regimen. Ultimately, the patient developed
symptoms akin to bowel obstruction and a CT scan re-
vealed small bowel distention with multiple air-fluid
levels (Figure 3). Considering possible mechanical bowel
obstruction surgery was consulted and the patient under-
went small bowel resection of the terminal ileum and
cecum. However, no tumorous obstruction was found and
histologic examination of the resected sample revealed in-
tense lymphoplasmacytic infiltration consistent with my-
enteric ganglioneuritis as this is typically found in CIPO
Figure 2 Whole body PET scan using 18 F-FDG. PET scan shows
a left upper thorax tumor mass (arrow) and metastases to left
supraclavicular lymph nodes (arrow head).
Figure 3 CT scan of the abdomen. CT scan of the abdomen showing
a distention of small bowel loops with several air-fluid levels.
Taverna et al. Biomarker Research  (2014) 2:23 Page 3 of 6(Figure 4). Anti-Hu antibodies were positive with a titer of
1:640. Collectively, the laboratory and pathologic findings
were consistent with paraneoplastic CIPO with underlying
SCLC.
10 days after surgery the patient underwent a first cycle
of chemotherapy with cisplatin (80 mg/m2 on day 1 and
etoposide (100 mg/m2 on day 1–3) without any im-
provement of his bowel activities despite promotility
and anti-secretory agents including intravenous octreo-
tide (200 mcg, three times a day), metoclopramide
(10 mg, three times a day), and dexamethasone (20 mg,
once a day). He was given parenteral nutrition. The course
was complicated by neutropenic sepsis requiring treat-
ment with broad spectrum antibiotics. After successful
recovery the patient was given a second cycle of chemo-
therapy with cisplatin and etoposide. Anti-Hu antibody
levels re-checked prior to the second cycle of chemother-
apy demonstrated marked improvement with titers down
to 1:160 from 1:640. Repeated CT scan of the chest shortly
after the second cycle of chemotherapy revealed substan-
tial shrinkage of the primary tumor and the metastases,
however bowel function remained absent. Unfortunately,
while neutropenic after the second cycle of chemotherapy
the patient developed severe sepsis requiring intubation
and intensive care medicine. Despite all the efforts the pa-
tient died from multi-organ failure.
Discussion
Paraneoplastic disorders are present in 7-10% of the
cancer patients with malignancies, while paraneoplastic
neurological syndromes (PNS) are observed only in 0.01%
of cancer patients. PNS are mainly associated with lung,
breast, ovarian, and stomach cancer [1,6,7]. Limbic en-
cephalitis, opsoclonus-myoclonus, cerebellar degeneration,
stiff person syndrome, retinopathy, CIPO, peripheral neu-
ropathy, Lambert-Eaton syndrome, and myasthenia gravis
are examples of PNS (Table 1) [7,8]. Neurologic mani-
festations associated with these diseases are clinically
important because it was found that more than 80% of
PNS precede the diagnosis of underlying malignancy [9].
Moreover, PNS are thought to be associated with favorable
prognosis and better outcome, as suggested in SCLC pa-
tients [1,10,11].
CIPO is characterized by signs and symptoms of mech-
anical bowel obstruction in the absence of an anatomic
lesion [12]. CIPO is idiopathic in most cases. Etiologies
causing CIPO include neurologic, endocrine, collagen
vascular, paraneoplastic, infectious and genetic disor-
ders (Table 2) [12-14]. Histological features of CIPO in-
clude myenteric plexus infiltration with plasma cells and
lymphocytes associated with axonal and neuronal degen-
eration [15,16]. Although paraneoplastic CIPO has been
reported in connection with several solid tumors, SCLC
and carcinoid tumors are by far the most common culprits
Figure 4 H & E stains of resected sample of the small intestine. The myenteric plexi show an increased lymphoid infiltrate (100x, arrows), with a
few plexi having a rather dense lymphoplasmacytic infiltrate (400x, arrows) consistent with myenteric ganglioneuritis. Magnification as indicated.
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quently found to be positive in paraneoplastic, but not
in non-paraneoplastic CIPO, often precede the overt
manifestation of the underlying malignancy, rendering
these antibodies to be potentially diagnostic and prog-
nostic markers [2,19]. Anti-Hu antibodies are polyclonal
complement-fixing immunoglobulins directed against
nuclear proteins expressed in the neurons. A hypothesis
is that these antibodies, together with the extensive lym-
phoplasmacytic infiltration, interact with the enteric plexus
leading to its malfunction and, finally, to its irrevers-
ible damage resulting in un-correctable gut dysmotility
[5,20,21]. To date, a relationship between anti-Hu anti-
body titers and severity of the clinical symptoms couldTable 2 Etiologies of chronic intestinal pseudo-obstruction
Etiology Underlying disorders






Paraneoplastic Small cell lung cancer
Carcinoid tumor
Infectious Chagas disease
Chronic JC virus infection
Radiation or chemotherapy
induced
Post radiation or chemotherapy
Genetic Hirschsprung disease
Mitochondrial encephalopathy with lactic acido
stroke like episodes (MELAS)
Myoclonus epilepsy associated with ragged rednot be demonstrated and convincing data indicating that a
decrease in anti-Hu levels correlates with improved CIPO
or better prognostic outcome are lacking [22-24]. In
addition to CIPO, anti-Hu antibodies are also known to be
involved in paraneoplastic CNS dysfunctions such as
limbic encephalopathy and cerebellar degeneration as
well as other paraneoplastic motor and autonomic neu-
ropathies [20]. In general, anti-Hu antibodies associated
with paraneoplastic neurologic conditions are called anti-
Hu syndromes [20,25,26].
Treatment of paraneoplastic CIPO is rarely successful
[27-29]. Previous reports revealed the effect of prokinetic
as well as anti-secretory agents to be very limited [29].
The combination of chemotherapy with plasmapheresisMechanisms
Altered Ca signaling
Mitochondrial dysfunction
Antibody mediated neuron or smooth muscle
involvement
Antibody mediated inflammatory response and cellular
infiltration
Inflammatory change of the enteric nerve system
Associated with treatments
Associated with genetic abnormality of SOX10
sis and DNA polymerase γ
Filamin A
fibers (MERRF) L1 cell adhesion molecule
Thymidine phosphorylase
PTEN
RNA binding protein for multiple splicing 2 (RBPMS2)
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improvement in clinical outcome in most cases, although
anti-Hu antibodies were successfully removed from the
circulation [28]. The lack of clinical response despite the
removal of the anti-Hu antibodies is thought to be, at least
in part, due to irreversible neuronal damage [5]. The per-
sisting absence of bowel function in our patient despite
receiving chemotherapy could also be secondary due to
Ogilvie’s syndrome triggered by surgical procedure, critical
illness and/or chemotherapy. However, given the histo-
logical findings of lymphoplasmacytic infiltration of the
intestinal plexus and given the disease course, we believed
that paraneoplastic CIPO, and not Ogilvie’s syndrome,
was most likely the cause of the absent bowel function
in our patient [30]. Recently, Badari et al. and Coret et al.
reported cases where patients with paraneoplastic CIPO
were partially successfully treated with either combination
treatment with rituximab (RTX) and cyclophosphamide
or RTX alone [8,31]. A hypothesized mechanism in this
scenario is that the inhibitory effect of RTX on B-cells
prevents them to function as efficient antigen-presenting
cells. This may result in a reduction of B-cell-triggered
cytotoxic T-cells, which are directed towards anti-Hu anti-
gens in neurons [31].
The mechanisms involved in anti-Hu antibody-associated
PNS appeared tightly linked to the development of a par-
tially efficient anti-tumor immune response [9-11].
Future goals to improve outcomes in paraneoplastic
CIPO and other PNS may include the development of ef-
fective immunotherapies. As mentioned, PNS often develop
prior to the diagnosis of cancer and anti-Hu antibodies
were found to be highly specific biomarkers for PNS in the
setting of SCLC [9,20]. As such, further studies may also
explore the question of whether anti-Hu antibodies can
serve as reliable markers for the early detection of SCLC
presenting with neurologic symptoms. If so, this may lead
to prompt treatment and better clinical outcome of SCLC.
Conclusion
Paraneoplastic CIPO is rare and difficult to treat. Symp-
tomatic treatments including plasmapheresis, prokinetic,
and anti-secretory agents have been tried, but without
significant benefit. Recent studies, however, have indicated
success with single agent and combined regimens with
RTX suggesting a role for immunomodulation in the treat-
ment of CIPO. Future studies focusing on understanding
the intricate pathophysiology associated with paraneoplas-
tic CIPO and other PNS will hopefully open new hori-
zons in the management of these rare and highly morbid
disorders.
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